ArticleNature cancer2023
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma.
Erratum issuedOpen access · hybridAbstract read
In one paragraph
Article in Nature cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 47 papers.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed
12.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 56 citations in OpenAlex.
- Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma.The New England journal of medicine · 2025Trial
- Review
- IL-17-driven tumor cell-intrinsic inflammatory programming creates an immunotherapy-permissive microenvironment.Molecular cancer · 2026Article
- Zinc finger protein-associated gene signature serves as a potential predictor for prognosis and therapeutic response in lung adenocarcinoma.Amino acids · 2026Article
- Plasma proteomics improves thrombosis prediction in patients with cancer and identifies targetable IL-17-driven endothelial activation.Science translational medicine · 2026Article
- Th17-mediated antitumor immunity in patient-derived organoid and autologous immune cell cocultures predicts response to immunotherapy in head and neck cancer.Immuno-oncology technology · 2026Article
- Uncovering the Intricate and Heterogeneous Cellular Microenvironment of Cutaneous Melanoma.Medicina (Kaunas, Lithuania) · 2026Review
- Cytokine Profiling in Cutaneous Melanoma: The Emerging Role of Interleukins in Prognostic Stratification with an Up-to-Date Overview of Published Data.Journal of personalized medicine · 2026Review
- Tumor microbiome-transcriptome crosstalk identifiesTheranostics · 2026Article
- BRAF mutation and tumor immune microenvironment in new era.American journal of cancer research · 2026Review
- Immunotherapy drug target identification using machine learning and patient-derived tumour explant validation.Nature machine intelligence · 2026Article
- Th17-like cells and immunosuppressive macrophages infiltrate tertiary lymphoid structures with distinct maturation status in soft-tissue sarcoma.Cell death & disease · 2025Article
- Saliva from oral squamous cell carcinoma patients promotes tumor progression via Inflammation, stromal remodeling, and metabolic reprogramming in a mouse model.BMC oral health · 2025Article
- Microbiome modulation uncouples efficacy and toxicity induced by immune checkpoint blockade in mouse multiple myeloma.Nature communications · 2025Article
- Anti-PD-L2 immunotherapy is efficacious against melanoma in aged hosts through IL-17 and IFNγ signalling.Nature communications · 2025Article
- Cordycepin Targets HRD1 to Promote Cancer Cell PD-L1 Ubiquitin-Proteasome Degradation and Increase Antitumor Immunity.MedComm · 2025Article
- Elucidating biomarkers of carcinogenesis in ulcerative colitis: insight from Mendelian randomization and transcriptomics.Discover oncology · 2025Article
- Article
- A Comprehensive Oncological Biomarker Framework Guiding Precision Medicine.Biomolecules · 2025Review
- Vinburnine potentiates anti-PD1 immunotherapy in melanoma through IL-24 secretion via P38/MAPK/ATF3 signaling.Journal of experimental & clinical cancer research : CR · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
30 authors at 9 institutions in 4 countries.
Renáta VáraljaiDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.ORCID http://orcid.org/0000-0001-6852-6859
Lisa ZimmerDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
Yahya Al-MataryDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
Paulien KapteinDivision of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.
Lea J AlbrechtDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
Batool ShannanDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
Jan C BraseNovartis Pharma AG, Basel, Switzerland.
Daniel GusenleitnerNovartis Institutes for BioMedical Research, Inc., Cambridge, MA, USA.
Teresa AmaralDepartment of Dermatology, University Hospital of Tübingen, Tübingen, Germany.
Nina WyssInstitute of Immunobiology, Kantonsspital St. Gallen, Switzerland, Switzerland.
Jochen UtikalSkin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Lukas FlatzDepartment of Dermatology, University Hospital of Tübingen, Tübingen, Germany.
Florian RambowDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
Hans Christian ReinhardtDepartment of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany.
Jenny DickDepartment of Immunodynamics, Institute of Experimental Immunology and Imaging, University Hospital Essen, Essen, Germany.ORCID http://orcid.org/0000-0002-4418-6092
Daniel R EngelDepartment of Immunodynamics, Institute of Experimental Immunology and Imaging, University Hospital Essen, Essen, Germany.
Susanne HornDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
Selma UgurelDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
Wiebke SondermannDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.ORCID http://orcid.org/0000-0002-3684-3523
Elisabeth LivingstoneDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
Antje SuckerDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
Annette PaschenDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.ORCID http://orcid.org/0000-0003-1651-1262
Fang ZhaoDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.ORCID http://orcid.org/0000-0002-2746-9242
Jan M PlackeDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
Jasmin M KloseDepartment of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Wolfgang P FendlerDepartment of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Daniela S ThommenDivision of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0002-7431-2854
Iris HelfrichDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.
Dirk SchadendorfDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany.ORCID http://orcid.org/0000-0003-3524-7858
Alexander RoeschDepartment of Dermatology, University Hospital Essen, West German Cancer Center, University Duisburg-Essen and the German Cancer Consortium (DKTK), Essen, Germany. alexander.roesch@uk-essen.de.ORCID http://orcid.org/0000-0002-0773-6067
Deutschen Konsortium für Translationale Krebsforschung · DEEssen University Hospital · DEKantonsspital St. Gallen · CHThe Netherlands Cancer Institute · NLUniversity of Duisburg-Essen · DENovartis (Switzerland) · CHNovartis (United States) · USUniversity Children's Hospital Tübingen · DEUniversity of Mannheim · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent studies suggest that BRAF
Indexed as
Interleukin-17MelanomaCTLA-4 AntigenHumansProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins B-rafCTLA-4 AntigenInterleukin-17Programmed Cell Death 1 ReceptorProto-Oncogene Proteins B-raf
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.